Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 3Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 846Carcinoma, Non-Small-Cell Lung 553Neoplasms 516Prostatic Neoplasms 503Lung Neoplasms 312Colorectal Neoplasms 304Multiple Myeloma 295Neoplasm Metastasis 255Melanoma 244Ovarian Neoplasms 215Leukemia, Myeloid, Acute 212Pancreatic Neoplasms 203Squamous Cell Carcinoma of Head and Neck 171Carcinoma, Renal Cell 166Stomach Neoplasms 160Recurrence 159Lymphoma 159Carcinoma, Hepatocellular 159Glioblastoma 151Brain Neoplasms 151Lymphoma, Non-Hodgkin 143Uterine Cervical Neoplasms 142Head and Neck Neoplasms 141Urinary Bladder Neoplasms 137Leukemia, Lymphocytic, Chronic, B-Cell 137Triple Negative Breast Neoplasms 136Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Hematologic Neoplasms 117Colonic Neoplasms 117Lymphoma, Follicular 114

Interventions

Paclitaxel 2Cisplatin 2Carboplatin 2cemiplimab 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Resectable Non-small Cell Lung Cancer × Clear all
NCT05247684 2026-03-05

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Akeso

Phase 2 Active not recruiting
90 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

NCT06161441 2026-01-12

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡